The Diabetes TeleCare Study (DTC)

/Home/Diabetes Treatment/Diabetes Clinical Trials - Active Not Recruiting

The Diabetes TeleCare Study (DTC)

This study is ongoing, but not recruiting participants.
Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Information provided by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
ClinicalTrials.gov Identifier: NCT00288132

Purpose
The American Diabetes Association clinical care guidelines stress the importance of metabolic control to prevent complications and improve quality of life for persons with diabetes. Unfortunately, these guidelines have not had widespread acceptance into clinical practice. Therefore, we propose translational research to evaluate telemedicine technology using interactive video conferencing (Diabetes TeleCare) as a novel means to increase the availability of health professionals in rural communities for the effective delivery of a diabetes self-management education program and as a means to provide retinal screenings in the primary care setting.

Condition Intervention
Diabetes Mellitus, Type 2
Behavioral: Intervention
Behavioral: Usual Care

MedlinePlus related topics: Diabetes
U.S. FDA Resources
Study Type:Interventional
Study Design:Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title:Bridging Barriers to Diabetes Care With Telemedicine: The Diabetes TeleCare Study (DTC)

Further study details as provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):

Primary Outcome Measures:
Hemoglobin A1c [ Time Frame: 6 mths, 12 mths, 24 mths ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
Blood pressure [ Time Frame: 6 mths, 12 mths, 24 mths ] [ Designated as safety issue: No ]

LDL Cholesterol [ Time Frame: 6 mths, 12 mths, 24 mths ] [ Designated as safety issue: No ]

Cost effectiveness and cost utility [ Time Frame: 6 mths, 12 mths ] [ Designated as safety issue: No ]

Retinal examination rates [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Weight [ Time Frame: 6 mths, 12 mths, 24 mths ] [ Designated as safety issue: No ]

Waist Circumference [ Time Frame: 6 mths, 12 mths, 24 mths ] [ Designated as safety issue: No ]

Enrollment:165
Study Start Date:August 2005
Estimated Study Completion Date:November 2008
Estimated Primary Completion Date:November 2008 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Usual Care: Active Comparator Behavioral: Usual Care
Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
Intervention: Experimental Behavioral: Intervention
A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted. The intervention goal was to achieve an A1c <7%, with secondary goals of 10% weight loss and increasing exercise to at least 30 minutes a day, 5 days a week. Participants attend 13 sessions, 2 in the first month (1 group, 1 individual), monthly thereafter (9 group, 2 individual). Three group sessions were conducted in-person, all others were conducted via telemedicine. The self-management education team consisted of an RN/CDE and an RD. Sessions were conducted remotely, with a trained facilitator (LPN) at the clinic site. Participants were given a notebook and new material was added at each session. Completion of self-monitoring logs, including blood sugar, diet and physical activity, was assigned daily followed by less frequently based on progress towards intervention goals.


Detailed Description:
According to recent 2002 estimates, the yearly cost of diabetes was approximately $132 billion. The burden of diabetes is considerable, particularly for ethnically diverse populations. Disease management programs that focus on self-management education have been effective in improving metabolic control. Accordingly, the American Diabetes Association clinical care guidelines stress the importance of metabolic control to prevent complications and improve quality of life for persons with this disease. Unfortunately, these advances have not resulted in widespread acceptance into clinical practice. Therefore, we propose translational research to evaluate telemedicine technology using interactive video conferencing (Diabetes TeleCare) as a novel means to increase the availability of health professionals in rural communities for the effective delivery of a diabetes self-management education program and as a means to provide retinal screenings in the primary care setting. Our aims are to 1) develop and implement a 12-month intervention, Diabetes TeleCare to improve adherence to diabetes clinical care guidelines and improve diabetes control in two community health centers located in ethnically diverse, rural and medically underserved communities, 2) conduct a one-year randomized clinical trial (RCT) of 200 patients to formally evaluate the effectiveness of Diabetes TeleCare compared to Usual Care in a sample with >60% African-Americans, and 3) determine the cost-effectiveness and satisfaction of Diabetes TeleCare compared to Usual Care. Participants are recruited from two community health centers in rural South Carolina and randomized according to a patient randomization schedule. Diabetes TeleCare (a structured curriculum) is delivered by a team consisting of a registered nurse/certified diabetes educator (RN-CDE) and an experienced registered dietitian, with support by other health professionals who are linked by interactive video conferencing to participants (single and group) in rural health centers at distant locations. The primary outcomes are measures of metabolic control (A1c, lipids), blood pressure, and use of the telemedicine-facilitated retinal screening capacity. Secondary outcomes include satisfaction, quality of life, health beliefs, and knowledge. The economic analysis will include an assessment of resource utilization, cost, and health utilities. In addition, incremental reductions in costs per A1c and the estimated lifetime cost-utility of Diabetes TeleCare compared to usual care will be determined. Telemedicine may be an effective alternative to traditional health care delivery systems resulting in improved diabetes education and control.

Eligibility
Ages Eligible for Study:21 Years and older
Genders Eligible for Study:Both
Accepts Healthy Volunteers:Yes
Criteria
Inclusion Criteria:

All participants must have a confirmed physician diagnosis of type 2 diabetes supported by American Diabetes Association diagnostic criteria for blood glucose levels or
Current use of oral hypoglycemic agents or insulin as confirmed by brief medical record review.
All adults (> 21 years of age) who have a A1c value > 7.0 will be eligible.
Exclusion Criteria:

Exclusion criteria applies to individuals with limitations that could limit safe participation in the study,

such as metastatic cancer,
multiple or recent (within six months) myocardial infarction (MI) or stroke,
dialysis for end stage renal disease,
severe psychiatric disease or dementia, or
inability to walk without an assistive device.
We will also exclude women who are pregnant at the time of study recruitment (based on self report only) because of the unique needs related to diabetes self-management during pregnancy.
We will, however, retain women in the study should they become pregnant during the course of the project.
Individuals will be excluded if they plan to move out of the area.
Additional exclusions may include inability to complete baseline tasks to the satisfaction of the lead interventionist or other more subjective assessment suggesting inability or unwillingness to adhere reasonably to the intervention based on interventionist review.
Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00288132

Locations
United States, South Carolina
CareSouth Bennettsville
Bennettsville, South Carolina, United States, 29512

Sponsors and Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
Principal Investigator: Richard M Davis, MD University of South Carolina

Responsible Party:University of South Carolina ( Richard M. Davis, Principal Investigator )
Study ID Numbers:67312, 5R18DK067312
First Received:February 6, 2006
Last Updated:April 18, 2008
ClinicalTrials.gov Identifier:NCT00288132 [history]
Health Authority:United States: Federal Government

Keywords provided by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK):
Diabetes
self-management
telemedicine
retinal
screening

Study placed in the following topic categories:
Metabolic Diseases
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders